Stifel Nicolaus cut shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) from a buy rating to a hold rating in a report published on Wednesday. They currently have $21.00 target price on the stock.

A number of other equities analysts also recently commented on VTAE. Zacks Investment Research downgraded shares of Vitae Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 13th. Wells Fargo & Co. downgraded shares of Vitae Pharmaceuticals from an outperform rating to a market perform rating in a research report on Sunday, September 11th. JMP Securities downgraded shares of Vitae Pharmaceuticals from an outperform rating to a market perform rating in a research report on Thursday, August 4th. Finally, Wedbush restated an outperform rating and set a $23.00 price objective on shares of Vitae Pharmaceuticals in a research report on Wednesday, May 25th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $19.05.

Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 20.95 on Wednesday. The firm’s market capitalization is $604.22 million. Vitae Pharmaceuticals has a 52-week low of $4.08 and a 52-week high of $20.95. The company’s 50-day moving average is $8.53 and its 200-day moving average is $8.41.

Vitae Pharmaceuticals (NASDAQ:VTAE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative net margin of 13,954.35% and a negative return on equity of 65.51%. The business’s revenue was down 98.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.45) earnings per share. Equities analysts predict that Vitae Pharmaceuticals will post ($1.64) earnings per share for the current year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 1,025,000 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $20.85, for a total value of $21,371,250.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey S. Hatfield sold 50,000 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the completion of the sale, the chief executive officer now directly owns 244,996 shares in the company, valued at $5,098,366.76. The disclosure for this sale can be found here. 14.80% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of VTAE. Handelsbanken Fonder AB boosted its stake in shares of Vitae Pharmaceuticals by 15.0% in the second quarter. Handelsbanken Fonder AB now owns 153,000 shares of the company’s stock worth $1,651,000 after buying an additional 20,000 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its stake in shares of Vitae Pharmaceuticals by 20.4% in the second quarter. Franklin Street Advisors Inc. NC now owns 100,800 shares of the company’s stock worth $1,088,000 after buying an additional 17,100 shares during the last quarter. Mitra Capital LLC acquired a new stake in shares of Vitae Pharmaceuticals during the first quarter worth approximately $2,671,000. BVF Inc. IL boosted its stake in shares of Vitae Pharmaceuticals by 1.3% in the first quarter. BVF Inc. IL now owns 2,089,014 shares of the company’s stock worth $13,850,000 after buying an additional 27,689 shares during the last quarter. Finally, Cormorant Asset Management LLC boosted its stake in shares of Vitae Pharmaceuticals by 178.3% in the first quarter. Cormorant Asset Management LLC now owns 1,735,000 shares of the company’s stock worth $11,503,000 after buying an additional 1,111,591 shares during the last quarter. 72.93% of the stock is currently owned by hedge funds and other institutional investors.

Vitae Pharmaceuticals Company Profile

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

5 Day Chart for NASDAQ:VTAE

Receive News & Ratings for Vitae Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.